Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity

Deanna M. Santer; Daniel Li; Yanal Ghosheh; Muhammad Atif Zahoor; Dhanvi Prajapati; Bettina E. Hansen; D. Lorne J. Tyrrell; Jordan J. Feld; Adam J. Gehring

doi:10.1038/s41467-022-34709-4

Nature Communications (Nov 2022)

Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity

Deanna M. Santer,
Daniel Li,
Yanal Ghosheh,
Muhammad Atif Zahoor,
Dhanvi Prajapati,
Bettina E. Hansen,
D. Lorne J. Tyrrell,
Jordan J. Feld,
Adam J. Gehring

Affiliations

Deanna M. Santer: Department of Immunology, University of Manitoba
Daniel Li: Institute of Medical Science, University of Toronto
Yanal Ghosheh: Toronto Centre for Liver Disease, University Health Network
Muhammad Atif Zahoor: Toronto Centre for Liver Disease, University Health Network
Dhanvi Prajapati: Department of Immunology, University of Manitoba
Bettina E. Hansen: Toronto Centre for Liver Disease, University Health Network
D. Lorne J. Tyrrell: Department of Medical Microbiology & Immunology, Li Ka Shing Institute of Virology, University of Alberta
Jordan J. Feld: Institute of Medical Science, University of Toronto
Adam J. Gehring: Institute of Medical Science, University of Toronto

DOI: https://doi.org/10.1038/s41467-022-34709-4
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 12

Abstract

Read online

The interferon response is a critical component response to SARS-CoV-2 infection and prior studies have established a role for the administration of PEGylated interferon-lambda1 and its impact on viral clearance. Here the authors show that PEGylated interferon-lambda1 accelerates the clearance of SARS-CoV-2 despite the negative impact of age on the host T cell response.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal